Rebecca A. Shatsky, MD, looks to the future of biomarker testing in metastatic breast cancer and offers advice to community oncologists.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Sacituzumab Govitecan/Pembrolizumab in HR+ Breast Cancer Show Nonsignificant PFS Increase
June 2nd 2024Progression-free survival was numerically improved with pembrolizumab plus sacituzumab govitecan vs sacituzumab govitecan alone in patients with HR-positive, HER2-negative metastatic breast cancer.
Read More